Diagnosis, classification, and cytogenetics of myelodysplastic syndromes

Haematologica

Volumn 83, Issue 3, 1998, Pages 258-275

  Vallespí, Teresa ^a   Imbert, Michèle ^b   Mecucci, Cristina ^c   Preudhomme, Claude ^d,e   Fenaux, Pierre ^d,e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY OF PERUGIA   (Italy)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Chromosome changes; Dyshemopoiesis; FAB subtypes; MDS

Indexed keywords

CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DISEASE CLASSIFICATION; DYSERYTHROPOIESIS; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; REFRACTORY ANEMIA; REVIEW;

EID: 0031970275     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. San Miguel JF, Sanz GF, Vallespi T, del Cañizo MC, Sanz MA. Myelodysplastic syndromes. Crit Rev Oncol Hematol 1996; 23:57-93.
2. Verhoef GEG, Pittaluga S, De Wolf-Peeters C, Boogaerts MA. FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol 1995; 71:3-11.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposais for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
4. Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologie variants. Semin Hematol 1996; 33:95-110.
5. Fenaux P. Myelodysplastic syndromes. Hematol Cell Ther 1996; 38:363-80.
6. Zhao L, van Oort J, Cork A, Liang JC. Comparison between interphase and metaphase cytogenetics in detecting chromosome 7 defects in hematological neoplasias. Am J Hematol 1993; 43:205-11.
7. Kibbelaar RE, van Kamp H, Dreef EJ, et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 1992; 79:1823-8.
8. Chen Z, Morgan R, Berger CS, Sandberg AA. Application of fluorescence in situ hybridization in hematological disorders. Cancer Genet Cytogenet 1992; 63:62-9.
9. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, VardimanJW. Cytogenetic clonality in myelodysplastic syndromes studied by fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 1993; 81: 1580-5.
10. Gerritsen WR, Donohue J, Bauman J, et al. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescence in situ hybridization. Blood 1992; 80:217-24.
11. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268-76.
12. Head DR, Kopecky K, Bennett JM, et al. Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/ Southwest Oncology Group Cooperative Study. Cancer 1989; 64:2199-202.
13. Acin P, Florensa L, Andreu LL, Woessner S. Cytoplasmic abnormalities of erythroblasts as a marked for ringed sideroblasts in myelodysplastic syndromes [letter]. Eur J Haematol 1995; 54:276-8.
14. Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395-408.
15. Widell S, Hellström-Lindberg E, Kock Y, Lindberg M, Öst Å, Hast R. Peripheral blood neutrophil morphology reflects bone marrow dysplasia in myelodysplastic syndromes. Am J Hematol 1995; 49:115-20.
16. Goasguen JE, Bennett JM, Cox C, Hambley H, Mufti G, Flandrin G. Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome. Leuk Res 1991; 15:1159-65.
17. Mangi MH, Mufti GJ. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 1992; 79:198-205.
18. Rhoads CP, Barker WH. Refractory anemia: analysis of one-hundred cases. J Am Med Assoc 1938; 110:794-6.
19. Doll DC, List AF. Myelodysplastic syndromes: introduction. Semin Oncol 1992; 19:1-3.
20. Galton DAG. The myelodysplastic syndrome. Part I. What are they? Part II. Classification. Scand J Haematol 1986; 36(Suppl 45):11-20.
21. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71:305-12.
22. Hast R. Sideroblasts in myelodysplasia: their nature and clinical significance. Scand J Haematol 1986; 36 (Suppl 45):53-5.
23. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990; 74:45-52.
24. Vallespí T, López F, Sanz G, et al. Refractory anaemia with ring sideroblasts (RAS): a simple scoring system based on easily available parameters [abstract]. Leuk Res 1991; 15(Suppl):18.
25. Aul C, Germing U, Kobbe G, Giagounidis A, Gattermann A. Heterogeneity of acquired idiopathic sideroblastic anemia (AISA): results of a prospective follow-up study in 189 patients [abstract]. Leuk Res 1997; 21 (Suppl 1):S6.
26. Seigneurin D, Audhuy B. Auer rods in refractory anemia with excess of blasts: presence and significance. Am J Clin Pathol 1983; 80:359-62.
27. Öst Å, Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk Res 1992; 16:9-11.
28. Vallespí T, Sanz G, Torrabadella M, Irriguible D, Sanz MA. Auer rods in myelodysplastic syndromes (MDS): presence and significance [abstract]. Blood 1990; 76(Suppl 1):330a.
29. Seymour JF, Estey EH. The prognostic significance of Auer rods in myelodysplasia. Br J Haematol 1993; 85: 67-76.
30. Shepherd PCA, Ganesan TS, Galton DAG. Haematological classification of the chronic myeloid leukaemias. In: Goldman JM, ed. Chronic myeloid leukaemia. Baillière's Clin Haematol, Vol. 1. London: Baillière Tindall; 1987. p. 887-906.
31. Martiat P, Michaux JL, Rodhain J. The Groupe Français de Cytogénétique Hématologique. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML) comparison with Ph+ CML and chronic myelomonocytic leukemia. Blood 1991; 78:205-11.
32. Vallespí T, Torrabadella M, Juliá A, et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 1985; 61:83-92.
33. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 1994; 87: 746-54.
34. Germing U, Gattermann N, Aul C. Problems in the classification of CMML Dysplastic vs. proliferative type [abstract]. Leuk Res 1997; 21(Suppl 1):S4.
35. Cervera J, Sanz GF, Vallespí T, et al. Does WBC count really define two different subtypes of chronic myelomonocytic leukemia (CMML)? Analysis of a series of 119 patients [abstract]. Leuk Res 1997; 21(Suppl 1):S7.
36. Florensa L, Woessner S, Lafuente R, et al. In vitro granulopoiesis in myelodysplastic syndromes (MDS) according to the FAB classification. In: Schmalzl F, Mufti GJ, eds. Myelodysplastic syndromes. Berlin: Springer-Verlag, 1992. p. 22-32.
37. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Castoldi G. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 1997; 82:25-30.
38. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia 1996; 10:20-6.
39. Rosati S, Anastasi J, Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol 1996; 33:111-26.
40. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer 1988; 62:958-64.
41. Yoshida Y, Oguma S, Uchino H, Maekawa T. Refractory myelodysplastic anaemias with hypocellular bone marrow. J Clin Pathol 1988; 41:763-7.
42. Fohlmeister I, Fischer R, Mödder B, et al. Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. J Clin Pathol 1985; 38:1218-24.
43. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993; 66:117-22.
44. Appelbaum FR, Barrall J, Storb R, et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987; 15:1134-9.
45. Lorand-Metze I, Meira DG, Lima CSP, Vasallo J, Metze K. Criteria for the differential diagnosis between aplastic anemia and hypocellular myelodysplasia [abstract]. Leuk Res 1997; 21 (Suppl 1):S9.
46. Orazi A, Albitar M, Heerema NA, Haskins S, Neiman RS. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol 1997; 107:268-274.
47. Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int J Hematol 1993; 58:53-61.
48. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91:612-7.
49. Rios A, Cañizo MC, Sanz MA, et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990; 75:26-33.
50. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992: 48:208-14.
51. Sultan C, Sigaux F, Imbert M, Reyes F. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 1981; 49:11-6.
52. Imbert M, Nguyen D, Sultan C. Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis. Leuk Res 1992; 16:51-4.
53. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991; 78:161-6.
54. Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ, Mufti GJ. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol 1989; 71:499-504.
55. Watts EJ, Majer RV, Green PJ, Mavor WO. Hyperfibrotic myelodysplasia: a report of three cases showing haematological remission following treatment with prednisolone. Br J Haematol 1991; 78:120-2.
56. Gustke SS, Becker GA, Garancis JC, Geimer NF, Pisciotta AV. Chromatin dumping in mature leukocytes: a hitherto unrecognized abnormality. Blood 1970; 35: 637-58.
57. Felman P, Bryon PA, Gentilhomme O, et al. The syndrome of abnormal chromatin dumping in leucocytes: a myelodysplastic disorder with proliferative features? Br J Haematol 1988; 70:49-54.
58. Brizard A, Huret JL, Lamotte F, et al. Three cases of myelodysplastic-myeloproliferative disorder with abnormal chromatin clumping in granulocytes [letter]. Br J Haematol 1989; 72:294-5.
59. Jaén A, Irriguible D, Millá F, et al. Abnormal chromatin clumping in leucocytes: a clue to a new subtype of myelodysplastic syndrome. Eur J Haematol 1990; 45: 209-14.
60. Hasle H, Jacobsen BB, Pederson NT. Myelodysplastic syndromes in childhood: a population-based study of nine cases. Br J Haematol 1992; 81:495-8.
61. Jackson GH, Carey PJ, Gant AJ, Bown NP, Reid MM. Myelodysplastic syndromes in children [letter]. Br J Haematol 1993; 84:185-6.
62. Hasle H. Myelodysplastic syndromes in childhood-classification, epidemiology, and treatment. Leuk Lymphoma 1994; 13:11-26.
63. Tuncer MA, Pagliuca A, Hicsonmez G, Yetgin S, Ozsoylu S, Mufti GJ. Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. Br J Haematol 1992; 82:347-53.
64. Chessells JM. Myelodysplasia. Baillière's Clin Haematol 1991; 4:459-82.
65. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995; 85:1742-50.
66. Nair R, Athale UA, Iyer RS, et al. Childhood myelodysplastic syndromes: clinical features, cytogenetics and prognosis. Indian J Pediatr 1992; 59:443-8.
67. Guinan EC, Tarbell NJ, Tantravahi R, Weinstein HJ. Bone marrow transplantation for children with myelodysplastic syndromes. Blood 1989; 73:619-22.
68. Castro-Malaspina H, Childs B, Papadopoulos E, et al. T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes [abstract]. Leuk Res 1997; 21(Supp 1):S51.
69. Chan GC, Wang WC, Raimondi SC, et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia 1997; 11:206-11.
70. Castro-Malaspina H, Schaison G, Passe S, et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors. Cancer 1984; 54:675-86.
71. Haas OA, Gadner H. Pathogenesis, biology and management of myelodysplastic syndromes in children. Semin Hematol 1996; 33:225-35.
72. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Semin Hematol 1996; 33:256-73.
73. van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillière's Clin Haematol 1996; 9:57-85.
74. Farhi DC, Odell CA, Shurin SB. Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood. Am J Clin Pathol 1993; 100:270-5.
75. Cremin P, Flattery M, McCann SR, Daly PA. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7:745-6.
76. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 1992; 304: 1137-43.
77. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3 (Suppl 4):117-128.
78. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12:2527-34.
79. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale. Arizona, USA, on February 23-25, 1987. Cancer Genet Cytogenet 1988; 32:1-10.
80. Brusamolino E, Bernasconi C. Therapy-related myelodysplastic syndromes and acute leukemias. Leukemia 1992; 6(Suppl 4):23-5.
81. Rowley JD, golomb HM, Vardiman J. Nonrandom chromosomal abnormalities in acute non-lymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas. Blood 1977; 50:759-70.
82. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II [letter] Blood 1991; 78:1147-8.
83. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 1985: 65:1364-72.
84. Rosenbloom B, Schreck R, Koeffler HP. Therapy-related myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:707-22.
85. Mecucci C. FISH (fluorescent in situ hybridization): the second youth of cytogenetics [editorial]. Haematologica 1995; 80:95-7.
86. Knuutila S. Lineage specificity in haematological neoplasms. Br J Haematol 1997; 96:2-11.
87. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251:437-8.
88. Van den Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet 1997; 94:1-7.
89. Pedersen B, Jensen IM. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia 1991; 5:566-73.
90. Boultwood J, Lewis S, Wainscoat JS.The 5q-syndrome. Blood 1994; 84:3253-60.
91. Fairman J, Chumakov I, Chinault AC, Nowell PC, Nagarajan L. Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci USA 1995; 92:7406-10.
92. Le Beau MM, Espinosa R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 1993; 90:5484-8.
93. Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 1997; 94:6948-53.
94. Srivastava A, Boswell HS, Heerema NA, et al. KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. Cancer Genet Cytogenet 1988; 35:61-71.
95. Lerza R, Castello G, Sessarego M, Cavallini D, Pannacciulli I. Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12)(q33;p12-3). Br J Haematol 1992; 82:476-7.
96. Wessels JW, Fibbe WE, van der Keur D, et al. t(5;12) (q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet Cytogenet 1993; 65:7-11.
97. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307-16.
98. Raynaud SD, Baens M, Grosgeorge J, et al. Fluorescence in situ hybridization analysis of t(3;12)(q26;p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996; 88:682-9.
99. Wlodarska I, La Starza R, Baens M, et al. FISH characterization of new translocations involving TEL(ETV6) in a wide spectrum of hematologic malignancies. Blood 1998; in press.
100. Wlodarska I, Mecucci C, Marynen P, et al. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995; 85:2848-52.
101. Peeters P, Wlodarska I, Baens M, et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997; 57:564-9.
102. Rege-Cambrin G, Mecucci C, Tricot G, et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 1987; 25:233-45.
103. Davis MP, Dewald GW, Pierre RV, Hoagland HC. Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet 1984; 12:63-71.
104. White NJ, Nacheva E, Asimakopoulos FA, Bloxham D, Paul B, Green AR. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood 1994; 83:2809-16.
105. Asimakopoulos FA, Holloway TL, Nacheva EP, Scott MA, Fenaux P, Green AR. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. Blood 1996; 87:1561-70.
106. Mitelman F. Catalog of chromosome aberrations in cancer. New York: Wiley-Liss; 1995.
107. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 1996; 95:219-26.
108. Campbell LJ, Garson OM. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 1994; 8:67-71.
109. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
110. Mecucci C, Van Orshoven A, Vermaelen K, et al. 11q-chromosome is associated with abnormal iron stores in myelodysplastic syndromes. Cancer Genet Cytogenet 1987; 27:39-44.
111. Dewald GW, Brecher M, Travis LB, Stupca PJ. Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. Cancer Genet Cytogenet 1989; 42:173-85.
112. Gattermann N, Aul C, Schneider W. Is acquired idiopathic sideroblastic anemia (AISA) a disorder of mitochondrial DNA? Leukemia 1993; 7:2069-76.
113. Cragg SJ, Drysdale J, Worwood M. Genes for the "H" subunit of human ferritin are present on a number of human chromosomes. Hum Genet 1985; 71:108-12.
114. Michaux L, Wlodarska I, Mecucci C, et al. Characterization by chromosome painting of balanced and unbalanced X chromosome translocations in myelodysplastic syndromes. Cancer Genet Cytogenet 1995; 82:17-22.
115. Pedersen-Bjergaard J, Philip P. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases. Br J Haematol 1987; 66:199-207.
116. Baurmann H, Cherif D, Berger R. Interphase cytogenetics by fluorescent in situ hybridization (FISH) for characterization of monosomy-7-associated myeloid disorders. Leukemia 1993; 7:384-91.
117. Shannon KM, Watterson J, Johnson P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 1992; 79:1311-8.
118. Pasquali F, Bernasconi P, Casalone R, et al. Pathogenetic significance of "pure" monosomy 7 in myeloproliferative disorders. Analysis of 14 cases. Human Genet 1982; 62:40-51.
119. Savage P, Frenck R, Paderanga D, Emperor J, Shannon KM. Parental origins of chromosome 7 loss in childhood monosomy 7 syndrome. Leukemia 1994; 8:485-9.
120. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 1995; 85:1985-99.
121. Vallespí T, Pujol A, Irriguible D. Trisomy 8 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [abstract]. Blood 1992; 80 (Suppl 1):462a.
122. Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7:499-508.
123. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7:1315-23.
124. Groupe Français de Cytogénétique Hématologique. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 1986; 21:11-30.
125. Pierre RV, Catovsky D, Mufti GJ, et al. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). The Sixth International Workshop on Chromosomes in Leukemia, London. Cancer Genet Cytogenet 1989; 40: 149-61.
126. García-Isidoro M, Tabernero MD, Najera ML, et al. Clinical and biological characteristics of myelodysplastic syndromes with nulisomy Y by FISH. Haematologica 1997; 82:537-41.
127. La Starza R, Matteucci C, Crescenzi B, et al. Trisomy 6 is the hallmark of a dysplastic clone in bone marrow aplasia. Cancer Genet Cytogenet 1998; in press.
128. Mecucci C, Rege-Cambrin G, Michaux JL, Tricot G, Van den Berghe H. Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. Br J Haematol 1986; 64:699-706.
129. Michaux L, Wlodarska I, Vellosa ERP, et al. Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. Cancer Genet Cytogenet 1996; 86:35-8.
130. Mecucci C, Tricot G, Boogaerts M, Van den Berghe H. An identical translocation between chromosome 1 and 15 in two patients with myelodysplastic syndromes. Br J Haematol 1986; 62:439-45.
131. Mugneret F, Dastugue N, Favre B, et al. Der(16)t(1;16) (q11;q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenetic and fluorescence in situ hybridization studies. Br J Haematol 1995; 90:119-24.
132. Soekarman D, von Lindern M, Daenen S, et al. The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with special clinical features. Blood 1992; 79: 2990-7.
133. Jotterand Bellomo M, Parlier V, Muhlematter D, Grob JP, Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992; 59: 138-60.
134. Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5) (q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12:265-75.
135. Cuneo A, Balboni M, Carli MG, et al. Involvement of erythrocytic and granulo-monocytic lineages bytrisomy 11 in two cases of acute myelomonocytic leukemia with tri-lineage myelodysplasia. An interphase cytogenetic study. Cancer Genet Cytogenet 1994; 77:33-8.
136. Moreau P, Talmant P, Milpied N, Garand R, Lefranc G, Harousseau JL. Trisomy 4 associated with acute lymphocytic leukemia [letter]. Br J Haematol 1991; 78:576.
137. Michaux L, Dierlamm J, Zeller W, et al. Trisomy 13 in myeloid malignancies: clinical, morphologic and immunologic correlations and characterization by combined immunophenotyping and interphase fluorescence in situ hybridization (FISH) [abstract]. Blood 1996; 88(Suppl 1):372a.
138. Mancini M, Cedrone M, Nanni M, et al. Trisomy 14 in hematologic diseases. Another non-random abnormality within myeloid proliferative disorders. Cancer Genet Cytogenet 1993; 66:39-42.
139. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet Cytogenet 1985; 17:189-255.
140. Mathew P, Tefferi A, Dewald GW, et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 1993; 81:1040-5.
141. Pedersen B. Anatomy of the 5q-deletion: different sex ratios and deleted 5q bands in MDS and AML Leukemia 1996; 10:1883-90.
142. Mecucci C, Van den Berghe H, Michaux JL, Bosly A, Doyen C. Paracentric inversions on the long arm of chromosome 5 in secondary myelodysplastic disorders [letter]. Cancer Genet Cytogenet 1987; 29:171-3.
143. Demetrick DJ, Dewald GW, Lanman J, Bahou WF. The thrombin receptor gene is centromeric to the common proximal breakpoint in patients with the 5q- syndrome: identification of a previously unrecognized chromosome 5 inversion. Br J Haematol 1996; 92:339-43.
144. Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995; 9:370-81.
145. Soenen V, Preudhomme C, Roumier C, Daudignon A, Lai JL, Fenaux P. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998; 91:1008-15.
146. Sessarego M, Ajmar F. Correlation between acquired pseudo-Pelger-Huët anomaly and involvement of chromosome 17 in chronic myeloid leukemia. Cancer Genet Cytogenet 1987; 25:265-70.
147. Fonatsch C, Gudat H, Lengfelder E, et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994; 8:1318-26.
148. Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosomes. Br J Haematol 1993; 83:158-65.
149. Ohyashiki JH, Ohyashiki K, Shimamoto T, et al. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2 and stem cell leukemia gene expression. Blood 1995; 85:3713-8.
150. Suzukawa K, Parganas E, Gajjar A, et al. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84:2681-8.
151. Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84:1243-8.
152. Suzukawa K, Sacoh H, Taniwaki M, Yokota J, Morishita K. The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome). Leukemia 1995; 9:1328-31.
153. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1-14.
154. Rubin CM, Larson RA, Anastasi J, et al. t(3;21) (q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 1990; 76:2594-8.
155. Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 1997; 82:364-70.
156. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci USA 1993; 90:7784-8.
157. Kurokawa M, Ogawa S, Tanaka T, et al. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene 1995; 11:833-40.
158. Gallagher A, Darley RL, Padua RA. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82:191-204.
159. Diverio D, Riccioni R, Mandelli F, Lo Coco F. The PML/RARα fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. Haematologica 1995; 80:155-60.
160. Sacchi S, Russo D, Awisati G, et al. All-trans retinoic acid in hematological malignancies. An update. Haematologica 1997; 82:106-21.